BR9814422A - Combinações de inibidor de ace - inibidor de mmp - Google Patents

Combinações de inibidor de ace - inibidor de mmp

Info

Publication number
BR9814422A
BR9814422A BR9814422-7A BR9814422A BR9814422A BR 9814422 A BR9814422 A BR 9814422A BR 9814422 A BR9814422 A BR 9814422A BR 9814422 A BR9814422 A BR 9814422A
Authority
BR
Brazil
Prior art keywords
inhibitor
combinations
mmp
ace
inhibitors
Prior art date
Application number
BR9814422-7A
Other languages
English (en)
Inventor
Joseph Thomas Peterson Jr
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814422(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9814422A publication Critical patent/BR9814422A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"COMBINAçõES DE INIBIDOR DE ACE - INIBIDOR DE MMP"<D>. Combinações de inibidores de ACE e de inibidores de MMP são úteis para retardar e reverter o processo de fibrose, dilatação ventricular e insuficiência cardíaca em mamíferos.
BR9814422-7A 1997-12-23 1998-11-10 Combinações de inibidor de ace - inibidor de mmp BR9814422A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23
PCT/US1998/023993 WO1999032150A1 (en) 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations

Publications (1)

Publication Number Publication Date
BR9814422A true BR9814422A (pt) 2000-10-10

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814422-7A BR9814422A (pt) 1997-12-23 1998-11-10 Combinações de inibidor de ace - inibidor de mmp

Country Status (24)

Country Link
US (1) US6133304A (pt)
EP (1) EP1047450B1 (pt)
JP (1) JP2001526245A (pt)
KR (1) KR20010033473A (pt)
AR (1) AR015504A1 (pt)
AT (1) ATE225187T1 (pt)
AU (1) AU751701B2 (pt)
BR (1) BR9814422A (pt)
CA (1) CA2305436A1 (pt)
CO (1) CO4970775A1 (pt)
DE (1) DE69808518T2 (pt)
DK (1) DK1047450T3 (pt)
ES (1) ES2184340T3 (pt)
HU (1) HUP0100427A3 (pt)
IL (1) IL135428A0 (pt)
IS (1) IS5446A (pt)
NO (1) NO20003256D0 (pt)
NZ (1) NZ503962A (pt)
PE (1) PE20000065A1 (pt)
PL (1) PL341335A1 (pt)
PT (1) PT1047450E (pt)
UY (1) UY25321A1 (pt)
WO (1) WO1999032150A1 (pt)
ZA (1) ZA9811794B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12462001A3 (sk) * 1999-03-03 2002-04-04 The Procter & Gamble Company Inhibítory metaloproteáz
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
KR100854424B1 (ko) 2001-01-29 2008-08-27 3-디멘져널 파마슈티칼즈 인코오포레이티드 치환된 인돌 및 인테그린 길항제로서의 이들의 용도
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
WO2003015762A1 (fr) * 2001-08-20 2003-02-27 Ono Pharmaceutical Co., Ltd. Agent therapeutique pour insuffisance cardiaque
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
EP1545287B1 (en) * 2002-10-04 2012-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Vasoregulating compounds and methods of their use
JP5068428B2 (ja) * 2002-11-07 2012-11-07 アメリカ合衆国 血管新生および抗血管新生療法のための標的
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP1660661A2 (en) * 2003-08-08 2006-05-31 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
CA2545855A1 (en) * 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
AU2005221151A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
EP1796681A2 (en) * 2004-08-02 2007-06-20 Genmedica Therapeutics SL Compounds for inhibiting copper-containing amine oxidases and uses thereof
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
CA2728766A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN102639134A (zh) * 2009-10-01 2012-08-15 和谐进化股份有限公司 使用基质金属蛋白酶-2抑制剂治疗动脉瘤样扩张、血管壁薄弱、特别是腹主动脉瘤和胸主动脉瘤的方法
CN103827095A (zh) 2011-08-30 2014-05-28 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
ES2765805T3 (es) 2011-08-30 2020-06-11 Chdi Foundation Inc Inhibidores de kinurenina-3-monoxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
US9884085B2 (en) 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
BR112017000922A2 (pt) 2014-07-17 2018-01-16 Chdi Foundation, Inc. métodos e composições para tratar distúrbios relacionados ao hiv
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097208T3 (es) * 1990-05-11 1997-04-01 Pfizer Composiciones y procedimientos terapeuticos y sinergicos.
DK0808172T3 (da) * 1995-02-10 2003-10-20 Searle & Co Kombinationer af angiotensinkonverterende enzyminhibitor og bivirkningsreducerende mængde af aldesteronantagonist
WO1997044315A1 (en) * 1996-05-17 1997-11-27 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
AU751701B2 (en) 2002-08-22
AR015504A1 (es) 2001-05-02
WO1999032150A1 (en) 1999-07-01
PT1047450E (pt) 2003-02-28
DK1047450T3 (da) 2003-01-27
HUP0100427A3 (en) 2002-11-28
US6133304A (en) 2000-10-17
AU1522099A (en) 1999-07-12
EP1047450B1 (en) 2002-10-02
DE69808518D1 (de) 2002-11-07
CO4970775A1 (es) 2000-11-07
ZA9811794B (en) 1999-06-29
NO20003256L (no) 2000-06-22
HUP0100427A2 (hu) 2001-06-28
ES2184340T3 (es) 2003-04-01
EP1047450A1 (en) 2000-11-02
UY25321A1 (es) 2004-07-30
NO20003256D0 (no) 2000-06-22
ATE225187T1 (de) 2002-10-15
PL341335A1 (en) 2001-04-09
IL135428A0 (en) 2001-05-20
IS5446A (is) 2000-04-14
KR20010033473A (ko) 2001-04-25
NZ503962A (en) 2002-03-28
PE20000065A1 (es) 2000-02-11
JP2001526245A (ja) 2001-12-18
CA2305436A1 (en) 1999-07-01
DE69808518T2 (de) 2003-06-26

Similar Documents

Publication Publication Date Title
BR9814422A (pt) Combinações de inibidor de ace - inibidor de mmp
BR9714385A (pt) Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular
BR9812371A (pt) Tratamento de distúrbio de conduta
NO963860L (no) Isoprenyl-transferase-inhibitorer
BR9908280A (pt) Inibidores de enzimas de fosfolipase
BR9812357A (pt) Tratamento de distúbio oposicional desafiador
CY2011015I2 (el) ΑΜΙΔΙΑ δ-AMINO-γ-ΥΔΡΟΞΥ-ω-ΑΡΥΛΟ-ΑΛΚΑΝΙΚΟΥ ΟΞΕΟΣ ΜΕ ΙΔΙΟΤΗΤΕΣ ΑΝΑΣΤΟΛΗΣ ΕΝΖΥΜΩΝ, ΙΔΙΑΙΤΕΡΑ ΤΗΣ ΡΕΝΙΝΗΣ
ATE423557T1 (de) Carbocyclische kaliumkanalhemmer
NO962269D0 (no) Enzyminhibitorer
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
ES2195970T3 (es) L-ribavirina y usos de la misma.
DK1017692T3 (da) 4-Heteroaryl-tetrahydroquinoliner og deres anvendelse som inhibitorer af cholesterolester-transferproteiner
BR9710994A (pt) Derivados anticonvulsivos úteis no tratamento de obesidade.
DK199901518A (da) I form af små molekyler foreliggende inhibitorer af rotamase-enzymaktivitet
FI880464A0 (fi) Bekaempningsmedel mot tandplaque och -karies.
EP0935963A3 (en) The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders
NO20033742L (no) Omega-aminoalkylamider av R-2-arylpropionsyrer som inhibitorer av polymofonukle¶re og mononukle¶re cellers kjemotakse
KR950700323A (ko) 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 아미노아세틸머캅토아세틸아미드 유도체(Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE)
WO1999020260A3 (en) The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
DK0885881T3 (da) Sulfonylalkanoylaminohydroxyethylaminosulfaminsyrer, der er anvendelige som retrovirale proteaseinhibitorer
BR0011291A (pt) Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz
ES2168384T3 (es) Derivados de 2-amino-1,2,3,4-tetrahidronaftaleno activos para el sistema cardiovascular.
FI880960A (fi) Anvaendning av rnas l inhibitor som markeringsaemne i virusinfektioner.
NO20005301D0 (no) Pyrrolidiner som inhibitorer av neuraminidaser
EA199901074A1 (ru) Соединенный прогон с двумя или более примыкающими друг к другу с перехлестом в продольном направлении деревянными балками, а также крепежный элемент для соединения двух перехлестывающихся концевых зон деревянных балок для использования в прогоне

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1928 DE 18/12/2007.